Assessment of atherosclerosis risk due to the homocysteine-asymmetric dimethylarginine-nitric oxide cascade in children taking antiepileptic drugs

Seizure

Volumn 22, Issue 2, 2013, Pages 124-127

  Emeksiz, Hamdi Cihan ^a   Serdaroglu, Ayse ^a   Biberoglu, Gürsel ^a   Gulbahar, Ozlem ^a   Arhan, Ebru ^a   Cansu, Ali ^b   Arga, Mustafa ^a   Hasanoglu, Alev ^a  

^a GAZI UNIVERSITY   (Turkey)

^b KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Antiepileptics; Asymmetric dimethylarginine; Atherosclerosis; Homocysteine; Nitric oxide

Indexed keywords

ANTICONVULSIVE AGENT; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; OXCARBAZEPINE; VALPROIC ACID;

ARTICLE; ATHEROSCLEROSIS; BENIGN CHILDHOOD EPILEPSY; BLOOD LEVEL; CARDIOVASCULAR RISK; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; TREATMENT DURATION;

ADOLESCENT; ANTICONVULSANTS; ARGININE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARBAMAZEPINE; CHILD; EPILEPSY; FEMALE; HOMOCYSTEINE; HUMANS; MALE; NITRIC OXIDE; PROSPECTIVE STUDIES; RISK FACTORS; VALPROIC ACID;

EID: 84873412523     PISSN: 10591311     EISSN: 15322688     Source Type: Journal    
DOI: 10.1016/j.seizure.2012.11.007     Document Type: Article

References (37)

1. G.S. Berenson, S.R. Srinivasan, W. Bao, W.P. Newman 3rd, R.E. Tracy, and W.A. Wattigney Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study The New England Journal of Medicine 338 1998 1650 1656
2. J.F. Annegers, W.A. Hauser, and S.B. Shirts Heart disease mortality and morbidity in patients with epilepsy Epilepsia 25 1984 699 704
3. S. Bramswig, T. Sudhop, C. Luers, K. von Bergmann, and H.K. Berthold Lipoprotein (a) concentration increases during treatment with carbamazepine Epilepsia 44 2003 457 460
4. O. Oz, Z. Gökçil, S. Bek, E. Cakir, and Z. Odabaşi Is asymmetric dimethylarginine responsible for the vascular events in patients under antiepileptic drug treatment? Epilepsy Research 87 2009 54 58
5. O. Ozdemir, A. Yakut, E.C. Dinleyici, S.D. Aydogdu, C. Yarar, and O. Colak Serum asymmetric dimethylarginine (ADMA), homocysteine, vitamin B(12), folate levels, and lipid profiles in epileptic children treated with valproic acid European Journal of Pediatrics 170 2011 873 877
6. M. Schwaninger, P. Ringleb, R. Winter, B. Kohl, W. Fiehn, and P.A. Rieser Elevated plasma concentrations of homocysteine in antiepileptic drug treatment Epilepsia 40 1999 345 350
7. U. Sener, Y. Zorlu, O. Karaguzel, O. Ozdamar, I. Coker, and M. Topbas Effects of common anti-epileptic drug monotherapy on serum levels of homocysteine, vitamin B12, folic acid and vitamin B6 Seizure 15 2006 79 85
8. A. Verrotti, S. Domizio, B. Angelozzi, G. Sabatino, G. Morgese, and F. Chiarelli Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants Journal of Paediatrics and Child Health 33 1997 242 245
9. L. Tümer, A. Serdaroǧlu, A. Hasanoǧlu, G. Biberoǧlu, and E. Aksoy Plasma homocysteine and lipoprotein (a) levels as risk factors for atherosclerotic vascular disease in epileptic children taking anticonvulsants Acta Paediatrica 91 2002 923 926
10. R. Siekmeier, T. Grammer, and W. März Roles of oxidants, nitric oxide, and asymmetricdimethylarginine in endothelial function Journal of Cardiovascular Pharmacology and Therapeutics 13 2008 279 297
11. R.H. Böger, S.M. Bode-Böger, and J.C. Frölich The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications Atherosclerosis 15 127 1996 1 11
12. T.M. Lu, Y.A. Ding, M.J. Charng, and S.J. Lin Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease Clinical Cardiology 26 2003 458 464
13. F. Schulze, H. Lenzen, C. Hanefeld, A. Bartling, K.J. Osterziel, and L. Goudeva Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study American Heart Journal 152 2006 493 e1-8
14. A. Ito, P.S. Tsao, S. Adimoolam, M. Kimoto, T. Ogawa, and J.P. Cooke Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase Circulation 99 1999 3092 3095
15. M.C. Stühlinger, P.S. Tsao, J.H. Her, M. Kimoto, R.F. Balint, and J.P. Cooke Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine Circulation 104 2001 2569 2575
16. E.C. Dinleyici, B. Kirel, O. Alatas, H. Muslumanoglu, Z. Kilic, and N. Dogruel Plasma total homocysteine levels in healthy children Turkiye Klinikleri J Pediatr 16 2007 1 7
17. M. Den Heijer, S. Lewington, and R. Clarke Homocysteine, MTHFR, and risk of venous thrombosis: a metaanalysis of published epidemiological studies J Thromb Haemost 3 2005 292 299
18. M. Huemer, B. Ausserer, G. Graninger, M. Hubmann, C. Huemer, and K. Schlachter Hyperhomocysteinemia in children treated with antiepileptic drugs is normalized by folic acid supplementation Epilepsia 46 2005 1677 1683
19. T. Jakubus, M. Michalska-Jakubus, K. Lukawski, A. Janowska, and S.J. Czuczwar Atherosclerotic risk among children taking antiepileptic drugs Pharmacological Reports 61 2009 411 423
20. A. Siniscalchi, F. Mancuso, L. Gallelli, G. Ferreri Ibbadu, N. Biagio Mercuri, and G. De Sarro Increase in plasma homocysteine levels induced by drug treatments in neurologic patients Pharmacological Research 52 2005 367 375
21. V. Belcastro, P. Striano, G. Gorgone, C. Costa, C. Ciampa, and D. Caccamo Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs Epilepsia 51 2010 274 279
22. S. Kurul, A. Unalp, and U. Yiş Homocysteine levels in epileptic children receiving antiepileptic drugs Journal of Child Neurology 22 2007 1389 1392
23. P.N. Patsalos, and E. Perucca Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs The Lancet Neurology 2 2003 473 481
24. M. Födinger, H. Buchmayer, and G. Sunder-Plassmann Molecular genetics of homocysteine metabolism Mineral and Electrolyte Metabolism 25 1999 269 278
25. A. Verrotti, R. Pascarella, D. Trotta, T. Giuva, G. Morgese, and F. Chiarelli Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine Epilepsy Research 41 2000 253 257
26. H. Karabiber, E. Sonmezgoz, E. Ozerol, C. Yakinci, B. Otlu, and S. Yologlu Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid Brain and Development 25 2005 113 115
27. H. Ono, A. Sakamoto, T. Eguchi, N. Fujita, S. Nomura, and H. Ueda Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants Metabolism: Clinical and Experimental 46 1997 959 962
28. G. Geda, H. Caksen, and D. Içaǧasioǧlu Serum lipids, vitamin B12 and folic acid levels in children receiving long-term valproate therapy Acta Neurologica Belgica 102 2002 122 126
29. M.A. Vilaseca, E. Monrós, R. Artuch, C. Colomé, C. Farré, and C. Valls Anti-epileptic drug treatment in children: hyperhomocysteinaemia, B-vitamins and the 677C → T mutation of the methylenetetrahydrofolate reductase gene European Journal of Paediatric Neurology 4 2000 269 277
30. T. Apeland, M.A. Mansoor, and R.E. Strandjord Antiepileptic drugs as independent predictors of plasma total homocysteine levels Epilepsy Research 47 1984 27 35
31. T. Tamura, K. Aiso, K.E. Johnston, L. Black, and E. Faught Homocysteine, folate, vitamin B-12 and vitamin B-6 in patients receiving antiepileptic drug monotherapy Epilepsy Research 40 2000 7 15
32. E. Alonso-Aperte, N. Ubeda, M. Achón, J. Pérez-Miguelsanz, and G. Varela-Moreiras Impaired methionine synthesis and hypomethylation in rats exposed to valproate during gestation Neurology 52 1999 10 750 756
33. S. Dayal, R.N. Rodionov, E. Arning, T. Bottiglieri, M. Kimoto, and D.J. Murry Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia American Journal of Physiology: Heart and Circulatory Physiology 295 2008 816 825
34. S.R. Lentz, R.N. Rodionov, and S. Dayal Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA Atherosclerosis 4 Suppl. 2003 61 65
35. T.F. Jonasson, T. Hedner, B. Hultberg, and H. Ohlin Hyperhomocysteinaemia is not associated with increased levels of asymmetric dimethylarginine in patients with ischaemic heart disease European Journal of Clinical Investigation 33 2003 543 549
36. P. Wanby, T. Teerlink, L. Brudin, L. Brattström, I. Nilsson, and P. Palmqvist Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population Atherosclerosis 185 2006 271 277
37. J. Thambyrajah, and J.N. Townend Homocysteine and atherothrombosis mechanisms for injury European Heart Journal 21 2000 967 974